SystImmune's BL-M17D1, an antibody-drug conjugate (ADC) with innovative linker and payload technology, has received FDA IND clearance for a Phase 1 clinical trial.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.